申请人:VERNALIS CAMBRIDGE LTD
公开号:WO2005021552A1
公开(公告)日:2005-03-10
Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer: wherein R2 is a group of formula -(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk' and Alk 2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=O)-, -(C=S)-, -S02-, -C(=O)O-, -C(=O) NR A- , -C(=S)NR A-, -S02NR A-, -NR AC(=O)_, -NR AS02- or-NR A-wherein R A is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group.
公式(1)的化合物是体外或体内HSP90活性的抑制剂,用于治疗癌症等疾病:其中R2是一个具有以下结构的基团 -(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q,其中Ar1是可选择取代的芳基或杂环芳基基团,Alk'和Alk 2是可选择取代的二价C1-C3烷基或C2-C3烯基基团,m、p、r和s独立取0或1,Z是-0-、-S-、-(C=O)-、-(C=S)-、-S02-、-C(=O)O-、-C(=O) NR A-、-C(=S)NR A-、-S02NR A-、-NR AC(=O)_-、-NR AS02-或-NR A-其中R A是氢或C1-C6烷基,Q是氢或可选择取代的碳环或杂环基团;R3是氢、可选取代基团,或可选择取代的(C1-C6)烷基、芳基或杂环芳基基团;R4是一个羧酸酯、羧酰胺或磺酰胺基团。